Fluad influenza vaccine latex issue

The Therapeutic Goods Administration has issued a safety advisory regarding Fluad trivalent influenza vaccine for people aged 65 and over, and a risk to patients with a latex allergy.

 

Consumers and health professionals are advised that, for the 2018 influenza season, natural rubber latex is present in the sheath covering the needle of trivalent influenza vaccine Fluad.

 

Fluad is available for people aged 65 years and over through the National Immunisation Program (NIP).

 

While reactions to latex are rare, anyone who has a severe allergy to latex should not receive Fluad.

 

Patients 65 and over can still be safely vaccinated with an alternative trivalent influenza vaccine, Fluzone High-Dose through the NIP.

 

There are no safety concerns regarding the vaccine itself.

 

The sponsor of Fluad, Seqirus, has committed to updating the Product Information of this vaccine accordingly.

 

If you, or someone you provide care for, has an allergy to latex, advise your health professional of this fact before receiving any influenza vaccination.

 

There is an alternative product available on the National Immunisation Program for those aged 65 and over.

 

If you have any questions or concerns about this issue, talk to your health professional.

 

23 April 2018.